Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis.
MetadataShow full item record
<h4>Background/aim</h4>Distinguishing true oligometastatic disease from early polymetastatic disease is vital in patients with soft tissue sarcoma as contemporary treatment strategies differ significantly. Clinical factors such as tumour biology, organ involved, number of lesions, and patient fitness influence clinical decisions.<h4>Patients and methods</h4>A retrospective search of a prospective database identified patients with new distant relapse, treated between 2009 and 2012.<h4>Results</h4>A total of 223 patients were included, and oligometastases were diagnosed in 81 (36%) patients, which were pulmonary in just over half of cases. These were treated with local therapy in 66 of 89 cases, and 7 patients received subsequent treatment for additional oligometastases. Metastasectomy was the most common treatment modality. A total of 16/66 patients (24%) underwent active surveillance for >6 months prior to local therapy.<h4>Conclusion</h4>Patients with oligometastatic disease can experience durable disease control with timely multimodality treatment approaches for evolving metastatic disease, where disease biology allows.
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Aged, 80 and over
Sarcoma Clinical Trials
Anticancer research, 2021, 41 (10), pp. 5089 - 5096